Markets see through Merck KGaA's focus on the future

28 September 2017

There was an emphasis on good times ahead in the communications put out by Merck KGaA (MRK: DE) as the German life sciences and pharma company welcomed analysts and investors to its 2017 Capital Markets Day on Thursday.

The company is on course to achieve its objectives for 2018, it was made clear, and chief executive Stefan Oschmann and chief financial officer Marcus Kuhnert gave a strategic outlook of the key growth drivers for the years 2019 to 2022.

By the end of the day, however, Merck’s share price had dropped by nearly 3% to 97.39 euros ($114.79).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK